NOVO NORDISK A/S-B (NOV.DE) Stock Fundamental Analysis
FRA:NOV • DK0062498333
41.7 EUR
+0.99 (+2.43%)
Last: Feb 13, 2026, 05:28 PM
Overall NOV gets a fundamental rating of 6 out of 10. We evaluated NOV against 55 industry peers in the Pharmaceuticals industry. NOV has an excellent profitability rating, but there are concerns on its financial health. NOV has a correct valuation and a medium growth rate. Finally NOV also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
- In the past year NOV was profitable.
- In the past year NOV had a positive cash flow from operations.
- Each year in the past 5 years NOV has been profitable.
- Each year in the past 5 years NOV had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of NOV (18.87%) is better than 98.18% of its industry peers.
- Looking at the Return On Equity, with a value of 52.79%, NOV belongs to the top of the industry, outperforming 94.55% of the companies in the same industry.
- The Return On Invested Capital of NOV (30.79%) is better than 98.18% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for NOV is significantly above the industry average of 14.21%.
- The 3 year average ROIC (43.61%) for NOV is well above the current ROIC(30.79%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.87% | ||
| ROE | 52.79% | ||
| ROIC | 30.79% |
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
1.3 Margins
- NOV's Profit Margin of 33.14% is amongst the best of the industry. NOV outperforms 100.00% of its industry peers.
- NOV's Profit Margin has been stable in the last couple of years.
- NOV has a better Operating Margin (41.30%) than 94.55% of its industry peers.
- NOV's Operating Margin has been stable in the last couple of years.
- Looking at the Gross Margin, with a value of 80.98%, NOV belongs to the top of the industry, outperforming 83.64% of the companies in the same industry.
- NOV's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 41.3% | ||
| PM (TTM) | 33.14% | ||
| GM | 80.98% |
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NOV is creating value.
- The number of shares outstanding for NOV remains at a similar level compared to 1 year ago.
- NOV has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, NOV has a worse debt to assets ratio.
2.2 Solvency
- NOV has an Altman-Z score of 4.07. This indicates that NOV is financially healthy and has little risk of bankruptcy at the moment.
- NOV's Altman-Z score of 4.07 is in line compared to the rest of the industry. NOV outperforms 52.73% of its industry peers.
- NOV has a debt to FCF ratio of 4.52. This is a neutral value as NOV would need 4.52 years to pay back of all of its debts.
- NOV's Debt to FCF ratio of 4.52 is in line compared to the rest of the industry. NOV outperforms 58.18% of its industry peers.
- NOV has a Debt/Equity ratio of 0.61. This is a neutral value indicating NOV is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.61, NOV is in line with its industry, outperforming 52.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 4.52 | ||
| Altman-Z | 4.07 |
ROIC/WACC4.58
WACC6.73%
2.3 Liquidity
- NOV has a Current Ratio of 0.80. This is a bad value and indicates that NOV is not financially healthy enough and could expect problems in meeting its short term obligations.
- NOV's Current ratio of 0.80 is on the low side compared to the rest of the industry. NOV is outperformed by 87.27% of its industry peers.
- NOV has a Quick Ratio of 0.80. This is a bad value and indicates that NOV is not financially healthy enough and could expect problems in meeting its short term obligations.
- NOV has a Quick ratio of 0.57. This is amonst the worse of the industry: NOV underperforms 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.57 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 3.01% over the past year.
- Measured over the past years, NOV shows a very strong growth in Earnings Per Share. The EPS has been growing by 20.95% on average per year.
- The Revenue has been growing slightly by 6.43% in the past year.
- Measured over the past years, NOV shows a quite strong growth in Revenue. The Revenue has been growing by 19.48% on average per year.
EPS 1Y (TTM)3.01%
EPS 3Y24.02%
EPS 5Y20.95%
EPS Q2Q%-0.29%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-8.98%
3.2 Future
- Based on estimates for the next years, NOV will show a small growth in Earnings Per Share. The EPS will grow by 6.65% on average per year.
- The Revenue is expected to grow by 5.90% on average over the next years.
EPS Next Y-2.28%
EPS Next 2Y1.88%
EPS Next 3Y6.76%
EPS Next 5Y6.65%
Revenue Next Year0.24%
Revenue Next 2Y3.47%
Revenue Next 3Y6.32%
Revenue Next 5Y5.9%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 13.37, NOV is valued correctly.
- Compared to the rest of the industry, the Price/Earnings ratio of NOV indicates a somewhat cheap valuation: NOV is cheaper than 74.55% of the companies listed in the same industry.
- NOV is valuated cheaply when we compare the Price/Earnings ratio to 27.97, which is the current average of the S&P500 Index.
- With a Price/Forward Earnings ratio of 13.68, NOV is valued correctly.
- Based on the Price/Forward Earnings ratio, NOV is valued a bit cheaper than 76.36% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of NOV to the average of the S&P500 Index (27.96), we can say NOV is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.37 | ||
| Fwd PE | 13.68 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, NOV is valued a bit cheaper than the industry average as 76.36% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, NOV is valued a bit more expensive than 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 47.75 | ||
| EV/EBITDA | 9.72 |
4.3 Compensation for Growth
- The excellent profitability rating of NOV may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.64
EPS Next 2Y1.88%
EPS Next 3Y6.76%
5. Dividend
5.1 Amount
- NOV has a Yearly Dividend Yield of 4.17%, which is a nice return.
- Compared to an average industry Dividend Yield of 1.94, NOV pays a better dividend. On top of this NOV pays more dividend than 83.64% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.79, NOV pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.17% |
5.2 History
- The dividend of NOV is nicely growing with an annual growth rate of 19.05%!
Dividend Growth(5Y)19.05%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- NOV pays out 50.53% of its income as dividend. This is a bit on the high side, but may be sustainable.
- NOV's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP50.53%
EPS Next 2Y1.88%
EPS Next 3Y6.76%
FRA:NOV (2/13/2026, 5:28:55 PM)
41.7
+0.99 (+2.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04 2026-02-04/bmo
Earnings (Next)05-05 2026-05-05
Inst Owners33.25%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap185.29B
Revenue(TTM)309.06B
Net Income(TTM)102.43B
Analysts71.88
Price Target54.04 (29.59%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.17% |
Yearly Dividend1.56
Dividend Growth(5Y)19.05%
DP50.53%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.64%
Min EPS beat(2)-7.04%
Max EPS beat(2)5.77%
EPS beat(4)2
Avg EPS beat(4)0.38%
Min EPS beat(4)-7.04%
Max EPS beat(4)5.77%
EPS beat(8)5
Avg EPS beat(8)1.56%
EPS beat(12)8
Avg EPS beat(12)1.83%
EPS beat(16)11
Avg EPS beat(16)1.95%
Revenue beat(2)0
Avg Revenue beat(2)-1.88%
Min Revenue beat(2)-3.19%
Max Revenue beat(2)-0.58%
Revenue beat(4)0
Avg Revenue beat(4)-1.33%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)-0.44%
Revenue beat(8)2
Avg Revenue beat(8)-0.05%
Revenue beat(12)5
Avg Revenue beat(12)0.38%
Revenue beat(16)8
Avg Revenue beat(16)0.73%
PT rev (1m)-1.65%
PT rev (3m)-11.79%
EPS NQ rev (1m)-5.7%
EPS NQ rev (3m)-11.39%
EPS NY rev (1m)-1.1%
EPS NY rev (3m)-11.16%
Revenue NQ rev (1m)-21.29%
Revenue NQ rev (3m)49.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.37 | ||
| Fwd PE | 13.68 | ||
| P/S | 4.48 | ||
| P/FCF | 47.75 | ||
| P/OCF | 11.62 | ||
| P/B | 7.13 | ||
| P/tB | 21.63 | ||
| EV/EBITDA | 9.72 |
EPS(TTM)3.12
EY7.48%
EPS(NY)3.05
Fwd EY7.31%
FCF(TTM)0.87
FCFY2.09%
OCF(TTM)3.59
OCFY8.6%
SpS9.31
BVpS5.85
TBVpS1.93
PEG (NY)N/A
PEG (5Y)0.64
Graham Number20.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.87% | ||
| ROE | 52.79% | ||
| ROCE | 39.01% | ||
| ROIC | 30.79% | ||
| ROICexc | 33.56% | ||
| ROICexgc | 59.2% | ||
| OM | 41.3% | ||
| PM (TTM) | 33.14% | ||
| GM | 80.98% | ||
| FCFM | 9.38% |
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
ROICexc(3y)50.94%
ROICexc(5y)53.03%
ROICexgc(3y)100.46%
ROICexgc(5y)105.49%
ROCE(3y)55.75%
ROCE(5y)58.53%
ROICexgc growth 3Y-22.89%
ROICexgc growth 5Y-7.78%
ROICexc growth 3Y-18.13%
ROICexc growth 5Y-11.63%
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
F-Score5
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 4.52 | ||
| Debt/EBITDA | 0.79 | ||
| Cap/Depr | 409.94% | ||
| Cap/Sales | 29.16% | ||
| Interest Coverage | 37.34 | ||
| Cash Conversion | 79.59% | ||
| Profit Quality | 28.3% | ||
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 4.07 |
F-Score5
WACC6.73%
ROIC/WACC4.58
Cap/Depr(3y)363.9%
Cap/Depr(5y)282.93%
Cap/Sales(3y)21.19%
Cap/Sales(5y)15.43%
Profit Quality(3y)60.31%
Profit Quality(5y)79.23%
High Growth Momentum
Growth
EPS 1Y (TTM)3.01%
EPS 3Y24.02%
EPS 5Y20.95%
EPS Q2Q%-0.29%
EPS Next Y-2.28%
EPS Next 2Y1.88%
EPS Next 3Y6.76%
EPS Next 5Y6.65%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-8.98%
Revenue Next Year0.24%
Revenue Next 2Y3.47%
Revenue Next 3Y6.32%
Revenue Next 5Y5.9%
EBIT growth 1Y-4.76%
EBIT growth 3Y19.04%
EBIT growth 5Y18.51%
EBIT Next Year13.84%
EBIT Next 3Y11.7%
EBIT Next 5Y9.7%
FCF growth 1Y-58.38%
FCF growth 3Y-23.26%
FCF growth 5Y-0.6%
OCF growth 1Y-1.54%
OCF growth 3Y14.72%
OCF growth 5Y18.05%
NOVO NORDISK A/S-B / NOV.DE FAQ
What is the fundamental rating for NOV stock?
ChartMill assigns a fundamental rating of 6 / 10 to NOV.DE.
Can you provide the valuation status for NOVO NORDISK A/S-B?
ChartMill assigns a valuation rating of 5 / 10 to NOVO NORDISK A/S-B (NOV.DE). This can be considered as Fairly Valued.
What is the profitability of NOV stock?
NOVO NORDISK A/S-B (NOV.DE) has a profitability rating of 9 / 10.
Can you provide the expected EPS growth for NOV stock?
The Earnings per Share (EPS) of NOVO NORDISK A/S-B (NOV.DE) is expected to decline by -2.28% in the next year.
Is the dividend of NOVO NORDISK A/S-B sustainable?
The dividend rating of NOVO NORDISK A/S-B (NOV.DE) is 7 / 10 and the dividend payout ratio is 50.53%.